Key result
TAVR performs similarly to SAVR for death or disabling stroke in intermediate-risk patients.
Why the study?
Does transcatheter aortic-valve replacement (TAVR) reduce death or disabling stroke in intermediate-risk patients compared to surgical aortic-valve replacement?
Does transcatheter aortic-valve replacement (TAVR) reduce death or disabling stroke in intermediate-risk patients compared to surgical aortic-valve replacement?
In intermediate-risk patients, TAVR provides similar outcomes to surgical aortic-valve replacement for the composite of death or disabling stroke.
Answers are grounded in this paper and cite their sources.
Supports TAVR as alternative in intermediate-risk patients; extends evidence from high-risk cohorts.
In intermediate-risk patients, TAVR was similar to surgical aortic-valve replacement with respect to the primary end point of death or disabling stroke. (Funded by Edwards Lifesciences; PARTNER 2 ClinicalTrials.gov number, NCT01314313.).
No takes yet. Share an insight, caveat, or question.
Leon et al. (2016) studied this question. In intermediate-risk patients, transcatheter aortic valve replacement (TAVR) had outcomes similar to surgical aortic valve replacement regarding death or disabling stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: